Streetbeat News

Regulatory

ECOR

electroCore, Inc. (NASDAQ:ECOR) has been granted a U.S. patent for systems and methods to treat PTSD using vagal nerve stimulation. The patent, U.S. Patent No. 11,865,329, covers the application of electrical impulses to the vagus nerve for 90 seconds to 3 minutes, which may consist of bursts of 2 to 20 pulses.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:10 pm

CRBP

The FDA has approved Corbus Pharmaceuticals' IND application for CRB-601, a TGFβ blocking monoclonal antibody. The company plans to begin Phase 1 trials in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:06 pm

DXR

Daxor Corporation has been granted a second patent by the United States Patent and Trademark Office for a clinical guidance system for blood volume management. This system uses unique blood volume metrics and related clinical measures to assist in fluid management interventions.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 1:04 pm

COIN

JNPR

Analysts predict Bitcoin ETFs could face premiums up to 8% amid high anticipation and lobbying efforts for approval. Cathie Wood's ARK Invest halts Coinbase selling and invests $8M in a chip giant. Emirates President highlights Boeing's quality control issues after a 737 Max 9 incident. Jim Cramer believes Bitcoin is topping out as ETF approval nears. Solana-based meme coin Bonk surges 30%. Former SEC Chair Jay Clayton sees Bitcoin ETF approval as inevitable. Juniper Networks' stock surges on news of a potential $13B acquisition by Hewlett Packard Enterprise.

Portfolio Pulse from Akanksha Bakshi

January 09, 2024 | 12:47 pm

AAPL

ALK

CRM

HPE

INTC

JNPR

MTCH

NVDA

QQQ

SPY

WBA

U.S. stock futures indicate a potential downtrend on Tuesday after Monday's rally, with traders eyeing the upcoming inflation report and big bank earnings. Despite caution, a tech merger, Bitcoin ETF optimism, and rising oil prices could drive buying. Boeing's issues with the 737 Max 9 affected the Dow, but it recovered thanks to gains in Apple, Intel, Salesforce, and Walgreens. Juniper Networks surged on acquisition news by Hewlett Packard Enterprise, while Match Group rose on Elliott Management's stake. The International CES and JPMorgan Healthcare Conference may impact related stocks. Oil prices and Bitcoin are up, while Asian markets closed mostly higher.

Portfolio Pulse from Shanthi Rexaline

January 09, 2024 | 12:35 pm

TNXP

Tonix Pharmaceuticals presented additional safety and tolerability data from the RESILIENT Phase 3 study of TNX-102 SL for fibromyalgia management at Biotech Showcase 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:17 pm

NUWE

Nuwellis has been granted a U.S. patent (#11865302) for an extracorporeal blood filtering machine and methods. This patent could potentially enhance the company's product portfolio and provide a competitive edge in the medical device market. The patent grant may also open up new opportunities for partnerships or licensing agreements, and it could serve as a barrier to entry for competitors.

Portfolio Pulse from Charles Gross

January 09, 2024 | 12:14 pm

MCRB

Seres Therapeutics has been granted FDA Fast Track designation for SER-155, a microbiome therapeutic aimed at preventing gastrointestinal-associated bacterial infections. The Phase 1b placebo-controlled Cohort 2 data for SER-155 is expected to be released in the third quarter of 2024.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:14 pm

CYN

Cyngn Inc. has been granted its 18th US patent, US-11,837,090-B2, for adaptive traffic rule-based decision making in autonomous driving. This technology is designed to optimize driving decisions for autonomous vehicles when faced with multiple environmental rules or constraints.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:09 pm

MDWD

MediWound announced that the FDA has accepted for review the supplement to the NexoBrid Biologics License Application (BLA) to include treatment for pediatric patients with severe thermal burns. This acceptance could potentially expand the use of NexoBrid to a broader patient population.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 12:03 pm